Please assess the completion status of the following clinical trial:

Trial Title: An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of study 6002-INT-001~* Not of childbearing potential~Exclusion Criteria:~* Cancer within 5 years of enrollment~* ALT/AST levels \> 2.5 times ULN

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).